Cangene

Rockville, United States Founded: 1998 • Age: 28 yrs Acquired By Emergent BioSolutions
Specialization in hyperimmunes, contract manufacturing, biopharmaceuticals, and biodefense is offered.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Cangene

Cangene is a company based in Rockville (United States) founded in 1998 was acquired by Emergent BioSolutions in December 2013. Cangene operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.

  • Headquarter Rockville, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Cangene

Premium access

Detailed funding history for Cangene

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Cangene

Cangene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Emergent BioSolutions.

All
Institutional
Investor Description Founded Year Domain Location
Vaccines for viral infections are developed by the company.
Locked Locked Locked
Premium access

Investor details for Cangene

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cangene

Investments
Premium access

Investment portfolio details for Cangene

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Cangene

Premium access

Detailed financials for Cangene

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cangene Comparisons

Cangene Primary company
Description
Specialization in hyperimmunes, contract manufacturing, biop...
Location
Rockville, United States
Founded Year
1998
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Cangene

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Cangene

Cangene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Targeted and immune-oncology drugs for cancer treatment are developed.
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Small molecules are developed for cancer and skin disease treatments.
Locked Locked Locked
ALX Oncology is focused on advancing cancer treatment therapies.
Locked Locked Locked
Therapeutic antibodies for cancer and other diseases are developed.
Locked Locked Locked
mRNA therapeutics platform is provided for multi-functional treatments.
Premium access

Detailed competitors of Cangene

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cangene

Premium access

Complete news archive for Cangene

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cangene

Cangene was founded in 1998.

Cangene is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.

Cangene was founded in 1998 and focused on biopharmaceuticals, particularly hyperimmunes and biodefense products. Operations included plasma-based antitoxins for anthrax, botulism, and vaccinia, with three items held in the U.S. Strategic National Stockpile. Manufacturing facilities were maintained in Winnipeg and Baltimore, alongside a plasma collection site in Winnipeg. Acquisition by Emergent BioSolutions occurred in 2013, relocating headquarters to Rockville, United States.

Cangene's top competitors include Moderna, BeiGene and Strand Therapeutics.

Cangene has 1 investor. Key investors include Emergent BioSolutions.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available